UK warns about differences between Tazocin and its generics
This article was originally published in Scrip
There are formulation differences between a branded injectable antibacterial product,Wyeth's Tazocin (piperacillin plus tazobactam), and recently approved generic versions that have the potential to cause serious medication errors because the generics have different compatibilities with other medicines compared with Tazocin, the UK regulator, the MHRA,has warned. Tazocin was reformulated last year, the agency notes.
You may also be interested in...
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.